HDFC Securities Broker Research reports

Indigo Paints - IPO Note Indigo Paints Ltd (IPL) the fifth largest company in the Indian decorative paint industry in terms of revenue from operations for Fiscal 2020 and the fastest growing amongst the top five paint companies in India.

Indian Railway Finance Corporation Limited - IPO Note Issue Snapshot: Issue Open: Dec 21 Dec 23, 2020, Price Band: Rs. 313 315, Issue Size: 9,523,345 eq shares (Fresh issue 2,698,413* + Offer for sale of 6,824,933 eq sh), Issue Size: Rs. 298.1 -300.0 cr Reservation for: QIB upto 50% eq sh Non Institutional atleast 15% eq sh Retail atleast 35% eq sh, Face Value: Rs 5, Book value: Rs 89.87 (Sep 30, 2020), Bid size: - 47 equity shares and in multiples thereof

Mrs. Bectors Food Specialities Limited IPO Note Issue Open: Dec 15 Dec 17, 2020 Price Band: Rs. 286 288 (Discount of Rs 15 for the eligible employees) *Issue Size: 18,768,750 eq shares (Fresh Issue of 1,407,639eq sh + Offer for sale of 17,361,111 eq sh) Issue Size: Rs. 536.8 540.5 cr Reservation for: QIB Upto 50% eq sh Non Institutional atleast 15% eq sh Retail atleast 35% eq sh Face Value: Rs 10 Book value: Rs 62.47 (September 30, 2020) Bid size: - 50 equity shares and in multiples thereof.

Burger King India Limited - IPO Note Issue Open: Dec 02 Dec 04, 2020 Price Band: Rs. 59 60 *Issue Size: 135,000,000 eq shares (Fresh Issue of 75,000,000eq sh + Offer for sale of 60,000,000 eq sh) Issue Size: Rs. 796.5 810.0 cr Reservation for: QIB atleast 75% eq sh Non Institutional Upto 15% eq sh Retail Upto 10% eq sh Face Value: Rs 10 Book value: Rs 7.62 (September 30, 2020) Bid size: - 250 equity shares and in multiples thereof 100% Book built Issue

Gland Pharma Ltd - IPO Note Issue Open: Nov 09 Nov 11, 2020 Price Band: Rs. 1490 1500 *Issue Size: 43,196,968 eq shares (Fresh Issue of 8,333,333 eq sh + Offer for sale of 34,863,635 eq sh) Issue Size: Rs. 6436.3 6479.5 cr Reservation for: QIB Upto 50% eq sh Non Institutional atleast 15% eq sh Retail atleast 35% eq sh Face Value: Rs 1 Book value: Rs 255.79 (June 30, 2020) Bid size: - 10 equity shares and in multiples thereof 100% Book built Issue Capital Structure: Pre Issue Equity: Rs. 15.49 cr Post issue Equity: Rs. 16.33 cr Listing: BSE & NSE

Equitas Small Finance Bank Limited - IPO Note Issue Open: Oct 20 Oct 22, 2020 Price Band: Rs. 32 33 Issue Size: 156,848,485 eq shares (Fresh Issue of 84,848,485 eq sh + Offer for Sale of 72,000,000 eq sh ) Issue Size: Rs. 501.9 517.6 cr Reservation for: QIB Upto 50% eq sh Non Institutional atleast 15% eq sh Retail atleast 35% eq sh Employee Reservation: Rs.1 cr EHL Shareholder Reservation: Rs 51.0 cr Face Value: Rs 10 Book value: Rs 26.47 (June 30, 2020) Bid size: - 450 equity shares and in multiples thereof

UTI Asset Management Company Limited - IPO Note Issue Open: Sept 29 Oct 01, 2020 Price Band: Rs. 552 554 Issue Size: 38,987,081 eq shares (Entirely Offer for sale) Issue Size: Rs. 2152.1 2159.9 cr Reservation for: QIB Upto 19,393,540 eq sh Non Institutional atleast 5,818,062 eq sh Retail atleast 13,575,479 eq sh Employee Upto 200,000 eq sh

Mazagon Dock Shipbuilders Limited - IPO Note Issue Open: Sept 29 Oct 01, 2020 Price Band: Rs. 135 145 Issue Size: 30,599,017 eq shares (Entirely Offer for sale) Issue Size: Rs. 413.1 443.7 cr Reservation for: QIB Upto 15,126,750 eq sh Non Institutional atleast 4,538,025 eq sh Retail atleast 10,588,725 eq sh Employee Upto 345,517 eq sh

Angel Broking Ltd - IPO Note Issue Size: Rs. 598.0 600.0 cr Reservation for: QIB Upto 50% eq sh Non Institutional atleast 15% eq sh Retail atleast 35% eq sh

We increase our target price to Rs5,054 to factor gRevlimid launch in FY23 and maintain our ADD rating. Key catalysts are launch of gVascepa, approval for gCopaxone and gNuvaring. Meaningful addition: Dr. Reddys settles patent litigation with Celgene (Bristol Myers Squibb) in the US for gRevlimid (USD7.6bn). The drug is indicated for multiple myeloma (cancer). As per the settlement terms, Dr. Reddys is licensed to sell volume-limited quantity after Mar 2022 and without volume-restriction after Jan 31, 2026 subject to product approval from the US FDA. While the details pertaining to launch date and market share are not disclosed, the opportunity can add an NPV of Rs384/share to our target price in a base case scenario (assuming 5-20% market share, 30-45% price erosion between FY23-26).